Abstract
Tuberculosis (TB) is an airborne communicable disease, mainly caused by aerobic, non-motile, rodshaped, weakly gram-positive, acid-fast tubercular bacillus Mycobacterium tuberculosis (MTb). Mycobacterium has worsened the problem in humans by acquiring various types of resistances like Multi-drug resistance (MDR), Single-drug resistance (SDR), and Extensive drug resistance (XDR). Some clinical problems and challenges associated with conventional TB chemotherapy include poor patient compliance, longer duration of chemotherapy, lesser cell permeability, primary drug resistance, difficulty in maintaining higher drug concentrations at the infected site, and degradation of the drug before reaching the target site. Thus, newer micrometric or nanometric carriers drug delivery approaches are needed. Colloidal (vesicular and particulate) drug carriers offer numerous advantages over conventional therapy such as better systemic bioavailability, rapid onset of therapeutic action, avoidance of first-pass metabolism, providing sustained and controlled release, fewer dosing frequencies, desired pharmacokinetic prole and route of administration. This review article present updates and fabrication of drug delivery approaches for tuberculosis chemotherapy in order to improve patient compliance.
Keywords: Colloidal systems, drug delivery, drug resistance, drug targeting, patient compliance, tuberculosis.
Current Pharmaceutical Design
Title:Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis
Volume: 21 Issue: 22
Author(s): Tarun Garg, Goutam Rath, Rayasa R. Murthy, Umesh D. Gupta, Palakkod G. Vatsala and Amit K. Goyal
Affiliation:
Keywords: Colloidal systems, drug delivery, drug resistance, drug targeting, patient compliance, tuberculosis.
Abstract: Tuberculosis (TB) is an airborne communicable disease, mainly caused by aerobic, non-motile, rodshaped, weakly gram-positive, acid-fast tubercular bacillus Mycobacterium tuberculosis (MTb). Mycobacterium has worsened the problem in humans by acquiring various types of resistances like Multi-drug resistance (MDR), Single-drug resistance (SDR), and Extensive drug resistance (XDR). Some clinical problems and challenges associated with conventional TB chemotherapy include poor patient compliance, longer duration of chemotherapy, lesser cell permeability, primary drug resistance, difficulty in maintaining higher drug concentrations at the infected site, and degradation of the drug before reaching the target site. Thus, newer micrometric or nanometric carriers drug delivery approaches are needed. Colloidal (vesicular and particulate) drug carriers offer numerous advantages over conventional therapy such as better systemic bioavailability, rapid onset of therapeutic action, avoidance of first-pass metabolism, providing sustained and controlled release, fewer dosing frequencies, desired pharmacokinetic prole and route of administration. This review article present updates and fabrication of drug delivery approaches for tuberculosis chemotherapy in order to improve patient compliance.
Export Options
About this article
Cite this article as:
Garg Tarun, Rath Goutam, Murthy R. Rayasa, Gupta D. Umesh, Vatsala G. Palakkod and Goyal K. Amit, Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis, Current Pharmaceutical Design 2015; 21 (22) . https://dx.doi.org/10.2174/1381612821666150531163254
DOI https://dx.doi.org/10.2174/1381612821666150531163254 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aging and Oral Health: Effects in Hard and Soft Tissues
Current Pharmaceutical Design Nonprofit Pharma: Solutions to What Ails the Industry
Current Medicinal Chemistry Human Leukocyte Antigens Class I and Class II: Associations and Distribution in Different Ethnic Groups of Patients with Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Predicting the Potential Public Health Impact of Disease-Modifying HIV Vaccines in South Africa: The Problem of Subtypes
Current Drug Targets - Infectious Disorders UPLC-ESI-Q-TOF/MS Based Metabolic Profiling of Protosappanin B in Rat Plasma, Bile, Feces, Urine and Intestinal Bacteria Samples
Current Drug Metabolism Epoxide Hydrolases and their Application in Organic Synthesis
Current Organic Chemistry Virtual Screening on Analogs of 2 Methyl Heptyl Isonicotinate as GlmU Inhibitors of Mycobacterium tuberculosis
Current Enzyme Inhibition Gene Expression Profiling Analysis to Identify Key Genes and Underlying Mechanisms in Meniscus of Osteoarthritis Patients
Combinatorial Chemistry & High Throughput Screening Antimicrobial Peptides and their Multiple Effects at Sub-Inhibitory Concentrations
Current Topics in Medicinal Chemistry Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases
Current Drug Metabolism Crystallization of Cytochromes P450 and Substrate-Enzyme Interactions
Current Topics in Medicinal Chemistry Cell-penetrating Peptides: Efficient Vectors for Vaccine Delivery
Current Drug Delivery Chelating Agents for Metal Intoxication
Current Medicinal Chemistry subject Index To Volume 2
Current Protein & Peptide Science Review of Pediatric Uveitis
Current Pediatric Reviews The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology A Review: The Anti-inflammatory, Anticancer and Antibacterial Properties of Four Kinds of Licorice Flavonoids Isolated from Licorice
Current Medicinal Chemistry Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients
Current HIV Research Retinoic Acid and Iron Metabolism: A Step Towards Design of a Novel Antitubercular Drug
Current Pharmaceutical Biotechnology